Skip to content
Home/Companies/Biotech/Q32 Bio

Q32 Bio

Biotech·US·Exited 2024·Held 4yr
Entry
2020
Hold
4yr
Exit
2024

Who owns Q32 Bio?

Q32 Bio was owned by Abingworth through Abingworth Bioventures VII (2018 vintage) from 2020 to 2024, exited via IPO.

Buyer identity available on Pro.

Hand-verified · updated 2026-06-10

Abingworth
Investor
Abingworth
Abingworth Bioventures VII · 2018 · Life Sciences VC

Key facts

HQUS
SectorBiotech
StatusActive
Exit Type
IPO
Buyer
MOIC
–
Exit Year
2024

More from Abingworth Bioventures VII

Other portfolio companies in the same fund.

Adicet Bio
Adicet Bio
Active
BiotechUS· 2021
Soteria Biotherapeutics
Soteria Biotherapeutics
Active
HealthcareUS· 2021
Atsena Therapeutics
Atsena Therapeutics
Active
BiotechUS· 2020
Orbus Therapeutics
Orbus Therapeutics
Active
HealthcareUS· 2020
Scorpion Therapeutics
Scorpion Therapeutics
Exited 2025
BiotechUS· 2020
to
Spruce Biosciences
Spruce Biosciences
Exited 2020
BiotechUS· 2020

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Q32 Bio

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Q32 Bio?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Q32 Bio.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue